title: Positron emission tomography imaging using radiolabeled inorganic nanomaterials.
abstract: CONSPECTUS: Positron emission tomography (PET) is a radionuclide imaging technology that plays an important role in preclinical and clinical research. With administration of a small amount of radiotracer, PET imaging can provide a noninvasive, highly sensitive, and quantitative readout of its organ/tissue targeting efficiency and pharmacokinetics. Various radiotracers have been designed to target specific molecular events. Compared with antibodies, proteins, peptides, and other biologically relevant molecules, nanoparticles represent a new frontier in molecular imaging probe design, enabling the attachment of different imaging modalities, targeting ligands, and therapeutic payloads in a single vector. We introduce the radiolabeled nanoparticle platforms that we and others have developed. Due to the fundamental differences in the various nanoparticles and radioisotopes, most radiolabeling methods are designed case-by-case. We focus on some general rules about selecting appropriate isotopes for given types of nanoparticles, as well as adjusting the labeling strategies according to specific applications. We classified these radiolabeling methods into four categories: (1) complexation reaction of radiometal ions with chelators via coordination chemistry; (2) direct bombardment of nanoparticles via hadronic projectiles; (3) synthesis of nanoparticles using a mixture of radioactive and nonradioactive precursors; (4) chelator-free postsynthetic radiolabeling. Method 1 is generally applicable to different nanomaterials as long as the surface chemistry is well-designed. However, the addition of chelators brings concerns of possible changes to the physicochemical properties of nanomaterials and detachment of the radiometal. Methods 2 and 3 have improved radiochemical stability. The applications are, however, limited by the possible damage to the nanocomponent caused by the proton beams (method 2) and harsh synthetic conditions (method 3). Method 4 is still in its infancy. Although being fast and specific, only a few combinations of isotopes and nanoparticles have been explored. Since the applications of radiolabeled nanoparticles are based on the premise that the radioisotopes are stably attached to the nanomaterials, stability (colloidal and radiochemical) assessment of radiolabeled nanoparticles is also highlighted. Despite the fact that thousands of nanomaterials have been developed for clinical research, only very few have moved to humans. One major reason is the lack of understanding of the biological behavior of nanomaterials. We discuss specific examples of using PET imaging to monitor the in vivo fate of radiolabeled nanoparticles, emphasizing the importance of labeling strategies and caution in interpreting PET data. Design considerations for radiolabeled nanoplatforms for multimodal molecular imaging are also illustrated, with a focus on strategies to combine the strengths of different imaging modalities and to prolong the circulation time.
authors: Center for Molecular Imaging and Translational Medicine, State Key Laboratory of Molecular Vaccinology and Molecular Diagnostics, School of Public Health, Xiamen University , Xiang'an South Road, Xiamen 361102, China.
authors: Xiaolian
authors: X
authors: Sun
authors: Weibo
authors: W
authors: Cai
authors: Xiaoyuan
authors: X
authors: Chen
mesh_terms: D000818:Animals; D006801:Humans; D007287:Inorganic Chemicals / Q000737:chemistry*; D007553:Isotope Labeling; D057054:Molecular Imaging; D049329:Nanostructures; D049268:Positron-Emission Tomography / Q000379:methods*
chemical_list: D007287:Inorganic Chemicals
references: J Nucl Med. 2007 Jun;48(6):18N, 21N
references: 17536102
references: J Am Chem Soc. 2014 Feb 5;136(5):1706-9
references: 24401138
references: J Nucl Med. 2002 May;43(5):693-713
references: 11994535
references: Analyst. 2012 Nov 7;137(21):4902-6
references: 22957337
references: Acc Chem Res. 2011 Oct 18;44(10):1114-22
references: 21732606
references: Adv Mater. 2014 Aug 13;26(30):5119-23
references: 24944166
references: J Nucl Med. 2006 Oct;47(10):1649-52
references: 17015901
references: ACS Nano. 2013 Apr 23;7(4):3498-505
references: 23473535
references: Sci Transl Med. 2014 Oct 29;6(260):260ra149
references: 25355699
references: J Am Chem Soc. 2010 Nov 3;132(43):15351-8
references: 20942456
references: Bioconjug Chem. 2008 Feb;19(2):391-402
references: 18072717
references: Angew Chem Int Ed Engl. 2013 Dec 9;52(50):13319-23
references: 24166933
references: Theranostics. 2014;4(3):290-306
references: 24505237
references: J Nucl Med. 2007 Nov;48(11):1862-70
references: 17942800
references: Acc Chem Res. 2013 Mar 19;46(3):743-9
references: 22786674
references: J Nucl Med. 2010 Jul;51(7):1123-30
references: 20554722
references: Angew Chem Int Ed Engl. 2014 Jan 3;53(1):156-9
references: 24272951
references: Br J Radiol. 2004 Feb;77(914):97-9
references: 15010379
references: Chem Rev. 2013 Feb 13;113(2):858-83
references: 23198879
references: Biomaterials. 2014 Dec;35(37):9868-76
references: 25224367
references: Nat Rev Cancer. 2002 Sep;2(9):683-93
references: 12209157
references: Sci Transl Med. 2014 Oct 29;6(260):260fs44
references: 25355696
references: Chem Commun (Camb). 2014 Feb 28;50(17):2170-2
references: 24430864
references: Biomaterials. 2013 Feb;34(7):1772-80
references: 23228423
references: Eur J Nucl Med Mol Imaging. 2008 Dec;35(12):2235-44
references: 18566815
references: Nano Lett. 2013 Feb 13;13(2):581-5
references: 23360442
references: Small. 2010 May 21;6(10):1087-91
references: 20473988
references: ACS Nano. 2011 Apr 26;5(4):3146-57
references: 21384900
references: J Nucl Med. 2004 Oct;45(10):1776-83
references: 15471848
references: Curr Radiopharm. 2011 Apr;4(2):131-9
references: 22191652
references: Acc Chem Res. 2009 Jul 21;42(7):832-41
references: 19530674
references: J Labelled Comp Radiopharm. 2014 Apr;57(4):239-43
references: 24497011
references: ACS Nano. 2014 May 27;8(5):4385-94
references: 24766522
references: Chem Rev. 2008 May;108(5):1501-16
references: 18426240
references: Nat Biotechnol. 2007 Oct;25(10):1165-70
references: 17891134
references: Nat Biotechnol. 2010 Dec;28(12):1300-3
references: 21057497
references: Acc Chem Res. 2011 Oct 18;44(10):883-92
references: 21548618
references: Acc Chem Res. 2008 Dec;41(12):1630-40
references: 18698851
references: Bioconjug Chem. 2000 Jul-Aug;11(4):527-32
references: 10898574
references: ACS Nano. 2012 Apr 24;6(4):3461-7
references: 22417124
references: Am J Nucl Med Mol Imaging. 2012;2(2):136-40
references: 23133808
references: Chem Soc Rev. 2014 Jan 7;43(1):260-90
references: 24173525
references: Biomaterials. 2014 Jan;35(2):856-65
references: 24344357
references: ACS Nano. 2011 May 24;5(5):3419-24
references: 21604811
references: Biomaterials. 2010 Apr;31(11):3016-22
references: 20092887
references: Nat Nanotechnol. 2007 Jan;2(1):47-52
references: 18654207
references: Nano Today. 2009 Oct 1;4(5):399-413
references: 20161038
references: Sci Transl Med. 2013 Dec 18;5(216):216rv4
references: 24353161
references: Nano Lett. 2011 Feb 9;11(2):814-9
references: 21210706
references: Med Chem. 2011 Sep;7(5):389-94
references: 21711221
references: Acc Chem Res. 2011 Oct 18;44(10):1050-60
references: 21919457
references: Science. 2004 Nov 5;306(5698):1009-12
references: 15528440
references: ACS Nano. 2014 Aug 26;8(8):8438-46
references: 25019252
references: Chem Rev. 2010 May 12;110(5):2858-902
references: 20415480
references: Arch Toxicol. 2011 Jul;85(7):751-73
references: 21479952
references: Acc Chem Res. 2013 Mar 19;46(3):761-9
references: 23964655